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Abstract
The human papillomavirus type 16 (HPV-16) E5 protein is an 83-amino-acid, hydrophobic polypeptide that has been localized to
intracellular membranes when overexpressed in COS-1 cells. While the HPV-16 E5 protein appears to modulate endosomal pH and signal
transduction pathways, genetic analysis of its biological activities has been hampered by low (usually nondetectable) levels of expression
in stable cell lines. Sequence analysis of the native HPV-16 E5 gene revealed that infrequent-use codons are used for 33 of its 83 amino
acids and, in an effort to optimize E5 expression, we converted these codons to those more common in mammalian genes. The modified
gene, 16E5*, generated protein levels that were six- to ninefold higher than those of wild-type HPV-16 E5, whereas the levels of mRNA
were unchanged. 16E5* protein was detectable in keratinocytes by immunoblotting, immunoprecipitation, and immunofluorescence
techniques and formed disulfide-dependent dimers and higher-order oligomers. Unlike the bovine papillomavirus E5 protein, which is
present in the Golgi, 16E5* was localized primarily to the endoplasmic reticulum and its expression reduced the in vitro life span of
keratinocytes.
© 2003 Elsevier Science (USA). All rights reserved.
Introduction
Infection with “high-risk” human papillomaviruses, such
as HPV types 16 and 18, plays a critical role in the devel-
opment of cervical intraepithelial neoplasia and invasive
cervical cancer (zur Hausen, 2001). The International
Agency for Research on Cancer (IARC, 1995) has declared
these “high-risk” viruses to be carcinogens and many stud-
ies have demonstrated that three early viral proteins (E5, E6,
and E7) exhibit transforming activity. The E6 and E7 pro-
teins, which are expressed in nearly all cervical cancers, are
able to transform rodent cell lines independently (Bedell et
al., 1989; Vousden et al., 1988) and can cooperate to im-
mortalize genital keratinocytes isolated from neonatal fore-
skin or cervical epithelium (Berger et al., 2002; Munger et
al., 1989). In contrast, the HPV-16 E5 protein, an 83-amino-
acid, membrane-associated protein (Bubb et al., 1988; Con-
rad et al., 1993; Halbert and Galloway, 1988), cannot im-
mortalize primary cells from either human or mouse
species. However, HPV-16 E5 can enhance the immortal-
ization of keratinocytes by E6/E7 (Stoppler et al., 1996) and
can potentiate the transforming activity of E7 in murine
fibroblasts (Valle and Banks, 1995). On its own, E5 can
induce the anchorage-independent growth of murine fibro-
blasts in which the epidermal growth factor receptor
(EGFR) is overexpressed (Leechanachai et al., 1992;
Straight et al., 1993) or potentiate the activation of the
EGFR in keratinocytes that naturally express high levels of
EGFR (Crusius et al., 1998; Pim et al., 1992; Straight et al.,
1993, 1995; Zhang et al., 2002). Although the HPV-16 E5
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protein can associate with the EGFR (Hwang et al., 1995),
E5 cannot directly activate the EGFR. Rather, it appears that
E5 augments EGFR signaling indirectly via inhibition of
endosome acidification, which consequently prevents recep-
tor downregulation (Straight et al., 1995). In the absence of
proper receptor downregulation, signaling pathways such as
MAPK are activated as well (Crusius et al., 1997; Gu and
Matlashewski, 1995). Many of these observations are com-
patible with the hypothesis that HPV-16 E5 inhibits endo-
somal acidification as a consequence of its binding the
16-kDa subunit of the vacuolar H-ATPase (Conrad et al.,
1993). However, contradictory findings have been reported
for the ability of various E5 mutants to bind the 16-kDa
protein and to interfere with vacuolar acidification in yeast
(Adam et al., 2000; Ashby et al., 2001). At least part of this
discrepancy may arise from the inability to detect the stable
expression of HPV-16 E5 protein, thereby making verifica-
tion of the stability and localization of the various E5
mutant proteins impossible. In the absence of direct data on
E5 protein expression, investigators have relied on Northern
analysis or reverse transcription polymerase chain reaction
(RT-PCR) to measure E5 mRNA levels, with the assump-
tion that protein levels were proportionate.
To date, studies have not addressed the underlying mech-
anism restricting E5 protein expression, although it has been
postulated that high levels of E5 might be incompatible with
cell viability. Following on the observation that the capsid
protein (L1) of papillomaviruses is regulated in part at the
posttranscriptional level by the presence of codons infre-
quently used in mammalian genes (Leder et al., 2001; Zhou
et al., 1999), we analyzed the sequence of the HPV-16 E5
gene and found that 33 of the 83 amino acids were encoded
by codons not frequently found in mammalian genes. In this
study we describe the synthesis of a new HPV-16 E5 gene,
designated 16E5*, in which we have replaced all of the
infrequently used codons in an effort to enhance protein
expression. We show that 16E5* generates much higher
levels of E5 protein which can now be localized predomi-
nantly in the endoplasmic reticulum. It was also observed
that high levels of E5 expression shortened the in vitro life
span of keratinocytes.
Results
Synthesis and expression of a codon-modified HPV-16 E5
gene (16E5*)
In an attempt to increase the expression level of E5, we
replaced all of the infrequently used codons with those more
frequently found in mammalian genes (Ausubel, 1994). The
codon-modified E5 gene, 16E5*, was constructed from syn-
thetic oligonucleotides using PCR as described under Ma-
terials and Methods (Table 1). The DNA and amino acid
sequences of the wild-type E5 gene are indicated in Fig. 1A,
with the infrequently used codons indicated in red. The
altered DNA sequence of the 16E5* gene is indicated above
the native codons. The amino acid sequence of this gene is
unaltered, except for the addition of a six-amino-acid
epitope (AU1) at the N terminus. This epitope was ap-
pended to facilitate immunologic detection.
Expression of the E5 protein was first examined by
immunofluorescence (IF) microscopy 48 h after transduc-
tion of keratinocytes. When examined with a Zeiss immu-
nofluorescence microscope, the cells transduced with the
16E5* gene displayed the highest levels of protein expres-
sion under identical conditions of staining and photographic
exposure (Fig. 1B). The staining pattern for the E5 protein
appeared to be perinuclear with extension into the cyto-
plasm, suggestive of ER localization. This was further eval-
uated in Fig. 3.
Quantification of 16E5* and wt16E5 protein and mRNA
expression in keratinocytes
To confirm the preliminary immunofluorescence findings
that the 16E5* protein was more abundant than wild-type
(wt) 16E5 protein, we also analyzed the retrovirus-trans-
duced cells by direct immunoprecipitation (IP) and by im-
munoprecipitation/immunoblotting (IP/IB). The results
shown in Fig. 2A are representative of four separate exper-
iments using different stocks of retroviruses as well as
different preparations of keratinocytes. The top two panels
show the relative levels of 16E5* and wt16E5 protein in
keratinocytes as determined by IP/IB and IP, respectively.
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By IP/IB the highest level of E5 protein was observed in the
16E5* cells, which contained ninefold more E5 protein than
the wt16E5 cells as determined by densitometry (numbers
under the respective lanes). By direct IP, the 16E5* cells
expressed sixfold more E5 protein than the wt16E5 (also
determined by densitometry).
To evaluate whether these large differences in E5 ex-
pression were specific for keratinocytes, we also examined
E5 expression in an NIH3T3 cell line (Fig. 2A). NIH3T3
cells were transfected with an empty vector LXSN or vec-
tors containing wt16E5 or 16E5* and selected in G418 (400
g/ml) for 21 days. These cells were analyzed by IP after
2.5 months in culture, at which time RT-PCR indicated that
both the wt16E5 and 16E5* cell line expressed E5 mRNA
(data not shown). The E5 protein was detectable only in the
fibroblast cells that were transfected with 16E5*, indicating
that the codon-optimized construct worked better than
wt16E5 in both epithelial and fibroblast cells (Fig. 2A,
bottom).
It was a possibility that the alterations in E5 protein
levels reflected changes in E5 mRNA levels rather than
efficiency of E5 mRNA translation. For example, increased
mRNA stability accounts for some of the alterations in L1
protein expression following alterations of codon usage
(Collier et al., 1998). To investigate this possibility, we
performed real time quantitative RT-PCR (QRT-PCR) to
determine the level of E5 RNA transcript present in the
transduced cells. The level of E5 mRNA expression was
normalized to the neomycin transcript from the same vector,
thereby providing an internal standard for vector expression
Fig. 2. 16E5* gene generates increased E5 protein levels without higher
mRNA levels. (A) Increased E5 protein levels detected by IP/IB and IP
methods. Primary keratinocytes were infected with the indicated retrovi-
ruses. Top: Cells were lysed in RIPA buffer and proteins were immuno-
precipitated with the AU1 antibody (4 l), separated on a 14 % gel, and
detected by Western blotting using the AU1 antibody at 1:1000. Middle:
Cells were metabolically labeled with [35S]methionine and [35S]cysteine
and lysed in RIPA buffer, and the E5 proteins were immunoprecipitated
with the AU1 antibody. Following electrophoresis, the E5 proteins were
visualized by autoradiography. Densitometry measurements were per-
formed on both the IP/IB and IP results and the relative level of 16E5*
(compared with wtE5). Standard deviations for the measurements were
1.2 and  0.9 for IP/IB and IP, respectively. Bottom: NIH3T3 cell lines
were metabolically labeled with [35S]methionine and [35S]cysteine as de-
scribed above and analyzed by IP for E5 expression. (B) Quantitative
RT-PCR determination of E5 mRNA levels in keratinocytes from upper
panel. Real time QRT-PCR (see Materials and Methods) was used to
evaluate the levels of E5 mRNA in keratinocytes transduced with the L
XSN vector (left lane), wt16E5 (middle lane), and 16E5* (right lane). The
levels of transcript represent the total level of mRNA in the cell lines as
compared with a standard curve generated using the same primers on
10-fold dilutions of the vector DNA. Top: Level of neomycin transcript for
each cell line. Middle: level of E5 RNA. The error bars indicate  SD. In
the Bottom: The relative level of E5 RNA expression has been standard-
ized to the level of neomycin RNA expression.
Fig. 1. Synthesis and expression of the 16E5* gene. (A) DNA sequence of
the native HPV-16 E5 gene (wt16E5) and the constructed, codon-opti-
mized HPV-16 E5 gene (16E5*). The infrequently used codons in the
native E5 sequence are indicated in red and the mutations that were
introduced into the 16E5* gene are indicated above. The single-letter code
for amino acids is given below the appropriate codon. (B) Expression of
AU1-tagged E5 proteins in primary keratinocytes. Primary keratinocytes
were infected with the indicated retroviruses and selected in G418 as
described. Left: LXSN empty retrovirus; middle: wt16E5; right: 16E5*.
Cells were fixed and stained with the AU1 antibody at 1:1000 and with
secondary goat anti-mouse conjugated to Texas red at 1:50. Hoechst dye
was also included with the secondary antibody to demonstrate the presence
of cells (inset).
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and allowing quantitative comparison of the expression be-
tween the wt16E5 and 16E5* retroviral constructs. E5 mR-
NAs were quantitated in the same cells used for the IP and
IP/IB experiments so that direct comparison could be made
between E5 mRNA expression and protein expression.
The results of the QRT-PCR are shown in Fig. 2B. The
top panel shows that the amount of neomycin RNA tran-
script in each of the indicated cell strains is very similar,
with only a 50% variation observed between the lowest
level (LXSN cells) and the highest level (16E5* cells). The
16E5* cells expressed approximately 30% more neomycin
transcript than the wtE5 cells. The middle panel shows that
the amount of E5 mRNA transcripts in the 16E5* and
wt16E5 cells varied similarly. The 16E5* cells expressed
about 66% more E5 transcript than the wtE5 cells. Thus,
when the level of E5 transcripts was normalized against the
level of neomycin transcript in the cell, 16E5* cells showed
only a 1.3-fold increase in the level of E5 RNA transcript
compared with wtE5 cells (bottom panel). Thus, it is most
likely that the 6- to 9-fold increase of E5 protein observed
in 16E5* cells is due primarily to changes in the efficiency
of mRNA translation.
Disulfide-dependent oligomerization of the HPV-16 E5
proteins
There are conflicting reports in the literature regarding
the ability of the HPV-16 protein to form dimers or higher-
order oligomers. For example, studies using protein ob-
tained from clinical material indicate that HPV-16 E5 can
apparently form dimers. However, the precise identity of the
protein band in the region of the “dimer” could not be
evaluated with this in vivo-derived sample (Kell et al.,
1994). In contrast, in vitro studies using an HPV-16 E5
protein tagged with a 20-amino-acid epitope failed to detect
dimer formation (Conrad et al., 1994). Although it was a
possibility that the epitope interfered with E5 self-associa-
tion, subsequent studies using native HPV-16 E5 also indi-
cated that there was little or no dimer formation (Hwang et
al., 1995). We decided to reinvestigate dimer formation by
HPV-16 E5 protein for three reasons: (1) increased protein
expression by 16E5* might allow for the detection of lower-
abundance oligomers; (2) the use of a smaller epitope (6
amino acids) might avoid potential artifacts generated by
previous studies with a 20-amino-acid epitope; and (3) the
BPV E5 protein, which exhibits hydrophobic interactions
similar to those of HPV-16 E5 (Conrad et al., 1993 Gold-
stein et al., 1991, 1994; Hwang et al., 1995; Petti and
DiMaio, 1992), can form multimers (Burkhardt et al.,
1987).
COS-1 cells were transfected with the wtE5 and 16E5*
plasmids and the E5 proteins extracted, immunoprecipi-
tated, and electrophoretically separated on gels under reduc-
ing and nonreducing conditions. Figure 3 demonstrates that
neither the AU1-tagged wtE5 nor 16E5* proteins formed
dimers or oligomers in the presence of mercaptoethanol
(lanes 2 and 3). However, under nonreducing conditions
(lanes 5 and 6), the E5 proteins could form dimers as well
as oligomers. This suggests that the cysteine residues of
HPV-16 E5 modulate this self-association, perhaps in a
fashion similar to that of the BPV-E5 protein where they
appear to stabilize hydrophobic interactions between adja-
cent E5 transmembrane domains.
Localization of HPV E5 in the endoplasmic reticulum
When expressed in COS-1 cells, both the HPV-16 and
BPV E5 proteins appear to localize to the ER and Golgi
apparatus (Conrad et al., 1993; Goldstein and Schlegel,
1990). Furthermore, the BPV E5 protein has been shown to
reside in the Golgi apparatus in fibroblasts, one of the
natural host cell for the bovine papillomavirus (Schapiro et
al., 2000). The result shown in Fig. 1B suggested that in the
natural host cell for HPV, the keratinocyte, the HPV E5
protein was not localized in the Golgi apparatus. Therefore,
in an attempt to determine where the E5 protein was local-
ized in keratinocytes, we performed immunofluorescence
studies with the aid of several organelle marker proteins,
calnexin (an ER membrane resident protein) (David et al.,
1993), TGN-38 (a Golgi resident protein) (Luzio et al.,
1990), and cellubrevin (an endosomal resident protein)
(McMahon et al., 1993), both of the latter fused to the green
fluorescent protein (GFP) (Miesenbock et al., 1998).
The results of the immunofluorescence studies are shown
in Fig. 4. In Fig. 4A, keratinocytes were examined for the
colocalization of an ER marker (calnexin) with the AU1-
Fig. 3. Disulfide-dependent oligomerization of the HPV-16 E5 protein. The
pJS55 (empty vector), wt16E5, and 16E5* plasmids were transfected into
COS-1 cells and 48 h later the synthesized E5 proteins were extracted with
RIPA buffer, immunoprecipitated with AU1 antibody, and electrophoreti-
cally separated under either reducing conditions (10% -mercaptoethanol)
or nonreducing condition (no mercaptoethanol). E5 protein was then de-
tected by immunoblotting with AU1. Under reducing conditions, both
wt16E5 and 16E5* migrated as a monomer of approximately 10–12 kDa
(lanes 2 and 3). Elimination of mercaptoethanol, however, resulted in both
E5 proteins assembling into apparent dimers, trimers, tetramers, and high-
er-order oligomers (lanes 5 and 6).
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tagged 16E5* protein. As anticipated, cells expressing
16E5* react with the AU1 antibody whereas control LXSN-
transduced cells do not. Following a merge of the rhodam-
ine-E5 image with the fluorescein-calnexin image, there is
nearly a complete conversion of staining to yellow, demon-
strating that most of the E5 colocalizes to the calnexin ER
compartment. In Fig. 4B, there is a small amount of con-
vergence between the rhodamine-E5 and fluorescein-
TGN-38 signals, although most of E5 is clearly not in the
Golgi. Fig. 4C shows that E5 is only minimally localized to
the early endosome compartment (cellubrevin). The image
of E5 in this panel does not exhibit the typical ER pattern
due to confocal focusing on a plane containing endosomes.
Thus, in contrast to the BPV-1 E5 protein that is localized
primarily in the Golgi, the HPV-16 E5 protein appears to be
selectively sequestered in the ER compartment.
Increasing the expression of HPV-16 E5 protein shortens
the life span of primary keratinocytes but does not induce
focus formation on NIH3T3 cells
During the course of this study it was observed that
keratinocytes expressing 16E5* appeared to grow poorly. In
an attempt to quantify this difference, keratinocytes trans-
duced with retroviruses were followed to determine the
number of passages that the cells could be maintained in
culture. The experiment was carried out a total of four times
(Fig. 5A). The number of passages that the control (LXSN)
keratinocytes could be carried varies slightly (8–10 passag-
Fig. 5. Biological effect of HPV E5 protein in keratinocytes and fibroblasts.
(A) HPV-16 E5 inhibits keratinocyte in vitro life span. Keratinocytes
transduced with the indicated control and E5 retroviruses were selected and
passaged as described under Materials and Methods. Briefly, cells were
allowed to reach 80% confluency before being split 1:5 and the total
number of passages was recorded for each cell line. The experiment was
performed four times. (B) HPV-16 E5 does not transform NIH 3T3 cells.
Stable NIH3T3 cell lines expressing pJS55 (empty vector), pJS16E5*
(HPV E5), or pJS63 (BPV E5) were used. NIH3T3 cells, without trans-
fection, were included as well to control for spontaneous transformation.
Duplicate plates were used in each experiment and the experiment was
carried out three times.
Fig. 4. 16E5* protein is localized primarily in the endoplasmic reticulum (ER).
Keratinocytes were transduced with empty retrovirus (LXSN) or 16E5*-
containing retrovirus and then fixed and stained with the designated antibodies
as described under Materials and Methods. Staining for calnexin (ER) was
performed using a rabbit polyclonal antibody (A) and fluorescein-tagged
secondary antibody. The TGN-38 (Golgi, B) and cellubrevin (early endo-
somes, C) proteins were also detected in the green channel due to the fused
GFP tag. In all middle panels, E5 was detected using the AU1 antibody and a
rhodamine-conjugated secondary antibody. Images were captured using Open-
Lab Version 3.0.7. The right-hand column shows the merged images, with the
highest coincidence observed with the calnexin/E5 antibodies. Images in (C)
were focused on a plane containing endosomes, thereby excluding the majority
of E5 signal localized in the ER.
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es), depending on the viability of the primary tissue, the
efficiency of keratinocyte isolation, and the passage at
which they were transduced (passages 1–3). The control
keratinocytes (LXSN) and the wtE5-transduced keratino-
cytes were very similar in their proliferative potential. Cells
transfected with 16E5*, however, showed a significant in-
hibition of life span, ranging from 20 to 50% of control.
Growth rate was affected in a similar manner (data not
shown).
Since the 16E5* construct showed augmented activity in
keratinocytes, we also analyzed its effect on fibroblasts, in
which a weak transforming activity has been reported for wt
HPV E5 (Straight et al., 1993). Stable NIH3T3 cell lines
transfected with empty vector, BPV E5, or pJS16E5* were
plated in a lawn of control NIH3T3 cells and grown for 3
weeks as described under Materials and Methods. As antic-
ipated, the BPV-1 E5 protein induced demonstrable focus
formation. The HPV-16E5* construct, however, failed to
induce foci and appeared similar to control 3T3 cells and the
vector control. The levels of 16E5* and BPV-1 E5 protein
expression in the respective cell lines were very similar as
determined by detection with the AU1 antibody (data not
shown). Thus, even though HPV-16 E5 protein has been
shown to bind to growth factor receptors, including the
platelet-derived growth factor receptor (Hwang et al.,
1995), it cannot induce foci on NIH3T3 fibroblasts.
Discussion
Studies of E5 biology and biochemistry have been very
difficult due to low protein expression levels, even when
employing inducible promoter systems (Crusius et al., 1997,
1998). Indeed, most studies have relied on indirect measures
of protein expression (e.g., RNA expression) and, as a
consequence, the published genetic studies of E5 are com-
promised by potential changes in protein stability and/or
localization. In addition, some of the apparently conflicting
activities of E5, including the ability to transform cells
(Straight et al., 1993; Valle and Banks, 1995) or to induce
cellular differentiation (Mayer and Meyers, 1998), may de-
rive from differences in expression levels. The main focus
of the current study was to examine the mechanism restrict-
ing the expression of the HPV-16 E5 protein in cultured
cells.
In vivo analysis has shown that basal keratinocytes con-
tain abundant mRNA transcripts that can encode for the E5
protein (Stoler et al., 1992; Tanimoto et al., 1991) and that
the E5 protein can be detected immunologically in the lower
third of the epithelium of low-grade squamous intraepithe-
lial lesions (SILs) and in the entire epithelium of high-grade
SILs (Chang et al., 2001). Together, these data suggest an
important role of E5 in the early infection of keratinocytes.
We have shown that replacing infrequently used codons
with those more commonly found in mammalian genes
allows for a 6- to 9-fold increase in the in vitro expression
of HPV-16 E5 protein in primary keratinocytes. We have
also shown, by the use of QRT-PCR, that the increased
protein level did not appear to be based on an increase in
mRNA abundance. This result differs somewhat from that
seen with the capsid protein (L1) of HPV in which altering
the sequence led to increased mRNA stability, contributing
to enhanced protein expression (Collier et al., 1998). While
our results suggest that keratinocytes could regulate E5
expression by differentiation-dependent variations in tRNA
species, there is currently no data addressing this possibility.
One of the first concerns of overexpressing an epitope-
tagged form of E5* was that there might be changes in
protein activity and/or intracellular localization. However,
our unpublished experimental results indicate that E5* is
virtually identical to native E5 in terms of previously de-
scribed biological activities. For example, E5* increased
EGFR phosphorylation in keratinocytes and induced EGF-
dependent, anchorage-independent growth of NIH3T3 cells.
E5* also altered intracellular pH in primary keratinocytes as
described for native E5 (Straight et al., 1995). The similar
activities of E5* and native E5 suggest that the AU1 epitope
has not significantly altered E5 function. Interestingly, pre-
vious studies demonstrating EGF-dependent, anchorage-in-
dependent growth of E5-expressing cells were performed
with a variant of 3T3 cells, 3T3-A31, in which the EGFR is
higher than in parent 3T3 cells. Our data with parent
NIH3T3 cells indicates that anchorage-independent growth
can be induced even in the absence of higher levels of
EGFR, as long as E5 is overexpressed.
The surprising observation in our study was that, in
primary keratinocytes, E5 is localized predominantly in the
ER compartment. Only small amounts of E5 appear in the
Golgi or in early endsosomes. In contrast, previous studies
have shown that the HPV-16 E5 protein binds the V-AT-
Pase 16K subunit (Conrad et al., 1993), alters endosomal pH
(Straight et al., 1995; Thomsen et al., 2000), and enhances
signaling via the EGF receptor (Crusius et al., 1998;
Leechanachai et al., 1992; Pim et al., 1992; Straight et al.,
1993; Zhang et al., 2002). This is strongly suggestive that
E5 is present in the endosomal compartment. Potentially E5
is present in endosomes but is either below the threshold for
detection by immunofluorescence or is masked by an asso-
ciated protein. Alternatively, E5 might be localized to the
ER but affect the endosomal pH via indirect mechanisms.
The ER appears to play a critical role in endocytosis and
downregulation of activated receptors (Haj et al., 2002).
The finding that HPV16 E5 is not concentrated in the
Golgi is in conflict with our previous localization studies
performed in COS-1 cells (Conrad et al., 1993). It is pos-
sible that overexpression of HPV-16 E5 in the COS-1 cell
system affected the distribution of E5 in intracellular com-
partments. When we examined 16E5* protein expression in
COS-1 cells, there was apparent staining of the perinuclear
Golgi region, but the staining did not correlate with the
localization of Golgi markers (data not shown). Evidently,
the perinuclear staining observed in the COS-1 cells is not
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Golgi-associated. Coordinate with this lack of Golgi local-
ization, we have been unable to demonstrate significant
alkalinization of the Golgi by HPV-16 E5 (unpublished
data). Only the BPV-1 E5 protein, which localizes to the
Golgi, results in trans-Golgi alkalinization.
The difference in the localization of the HPV and BPV
E5 proteins may account for the inability of the former to
induce foci in NIH3T3 cells. Both have been shown to bind
to growth factor receptors but, unlike BPV E5, HPV E5
cannot activate receptors in the absence of ligand. BPV E5
has been shown to bind to and activate the immature form
of the PDGFR (Goldstein et al., 1994; Petti and DiMaio,
1992; Petti et al., 1991), which might occur in the Golgi
apparatus before the receptor is glycosylated and trans-
ported to the cell surface. In contrast, the HPV E5 protein
most likely binds growth factor receptors in non-Golgi com-
partments such as the plasma membrane, endosomes, and
ER. The reliance of HPV-16 E5 activity on growth factor
addition (Crusius et al., 1998; Zhang et al., 2002) is com-
patible with its binding to externally exposed growth factor
receptors.
The observation that E5 appears to inhibit the growth of
primary keratinocytes was also surprising. It has been
shown that in the context of full-length HPV-16 DNA, E5
enhances the immortalization of primary keratinocytes
(Stoppler et al., 1996). Previous findings in primary and
immortalized keratinocytes suggest that E5 enhances the
activation of the EGFR in a ligand-dependent manner (Cru-
sius et al., 1998; Pim, et al., 1992; Straight et al., 1995;
Zhang et al., 2002). It has also been shown that signaling
through the EGFR appears essential for the survival of
primary keratinocytes (Rodeck et al., 1997). Based on these
findings, it might be anticipated that E5 would stimulate the
growth of keratinocytes due to an enhancement of receptor
activation. However, recent studies indicate that overex-
pression of the EGFR in primary keratinocytes actually
decreases their life span (Akerman et al., 2001), similar to
what we observe for HPV-16 E5. It is possible that aug-
mentation of EGFR signaling by HPV-16 E5 mimics over-
expression of EGFR.
One of the primary downstream effectors of the activated
EGFR is ras (reviewed in Yarden and Ullrich, 1988) and
oncogenic ras induces premature cellular senescence in
primary human and rodent cells unless there is a cooperat-
ing oncogene that disrupts the p53 or pRB pathway (Serrano
et al., 1997). In the presence of such an additional oncogene,
the oncogenic ras induces transformation. These results
suggest that too much signaling from growth factor recep-
tors in a primary cell is not well tolerated. This may explain
the observation that E5 (when expressed alone) inhibits the
in vitro longevity of keratinocytes, but, when co-expressed
with the E6 and E7 genes (which inactivate the cellular p53
and pRB pathways), it actually promotes keratinocyte trans-
formation and growth (Stoppler et al., 1996).
Materials and methods
Construction of a codon-modified HPV-16 E5 gene
Six sense strand (S1–S6) and six antisense strand (AS1–
AS6) oligonucleotides were synthesized (Table 1) and used
in PCRs to generate an HPV-16 E5 gene containing com-
monly used codons. The concept for gene synthesis using
synthetic oligonucleotides has been described previously
(Stemmer et al., 1995). The sense strand primers start at the
initiation codon and continue as contiguous oligonucleo-
tides, terminating approximately 20 bases from the end of
the gene. The antisense strand oligonucleotides start at the
stop codon for E5 and continue as contiguous oligonucleo-
tides, ending approximately 20 bases from the initiation
codon. In this manner, the overlapping oligonucleotides act
as primers for the opposite strand. By the end of the first
round of PCR, the full-length gene will have been synthe-
sized without any necessity for ligation.
All oligonucleotides were diluted to 1 g/l. A master
mix containing 2 l of each oligonucleotide was prepared.
In the first round of PCR, 1 l of the master mix, 4 l of 2
mM dNTP mix (Invitrogen), 5 l 10 PCR buffer (Invitro-
gen), 1 l 50 mM MgCl2, 38 l H2O, and 1 l Taq DNA
polymerase (Invitrogen) were subjected to the following
PCR conditions: 30 cycles at 94°C for 45 s, 55°C for 45 s,
and 72°C for 30 s. For the second round of PCR, flanking
oligonucleotides were used to incorporate cloning sites at
the beginning and end of the gene. The 5 oligonucleotide
sequence was 5 TTACATGGATCCGCCACCATGGA-
CACCTATCGCTATATAACAAATCTGGAT 3 and con-
tained a BamHI site, a Kozak consensus sequence (Kozak,
1987), and an AU1 epitope (Lim et al., 1990) at the N
terminus to allow for immunological detection. The 3 oli-
gonucleotide sequence was 5 ATGTAAGGATCCTTAT-
GTAATCAGAAAGCG 3 containing a BamHI site. The
PCR was 1 l of PCR from the first step, 4 l of 2 mM
dNTP mix, 5 l 10 PCR buffer, 1 l 50 mM MgCl2, 1 l
5 PCR oligonucleotide (20 mM), 1 l of 3 PCR oligonu-
cleotide (20 mM), 36 l H2O, and 1 l Taq DNA polymer-
ase. The PCR conditions included a hot start at 94° C for 3
min followed by 30 cycles of 94°C for 45 s, 48°C for 45 s,
and 72°C for 30 s. The fidelity of the resulting PCR product,
designated 16E5*, was verified by DNA sequencing, and
cloned into the LXSN retrovirus expression vector (Miller
and Rosman, 1989).
For comparative analysis, the wild-type E5 gene
(wt16E5) was also amplified from the full-length HPV-16
genome using the same conditions as for the second step
PCR. In this instance the 5 oligonucleotide sequence was 5
TTACATGGATCCGCCACCATGGACACCTATCGCT-
ATATAACAAATCTTGATACTGC-3, which incorpo-
rated a BamHI site, Kozak consensus sequence, and the
AU1 epitope tag between the first and second amino acids
of the E5 gene. The 3 oligonucleotide sequence was 5AT-
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GTAAGGATCCTTATGTAATTAAAAAGCG-3, which
introduced a BamHI site after the stop codon.
The wt16E5 and 16E5* LXSN retroviral vectors were
used to generate retrovirus stocks using the Phoenix cell
system (Pear et al., 1993).
Immunofluorescence microscopy
Retrovirus-transduced keratinocytes were plated in two
chambered slides (Labtek) and 48 h later were fixed in 3.7%
formaldehyde (Baker) for 15 min at room temperature. The
cells were then incubated in IF buffer (phosphate-buffered
saline (PBS, Invitrogen) containing 10% normal goat serum
(NGS, Sigma) and 0.1% saponin (Sigma)) for 30 min.
Localization of the AU1-tagged E5 protein and calnexin
(ER protein) was performed as follows. The AU1 antibody
(Covance) was diluted 1:1000 (stock 5–7 mg/ml) and the
calnexin antibody (Santa Cruz) was diluted 1:500 (stock
200 g/ml) in IF buffer and incubated for 1 h at room
temperature, after which the cells were washed extensively
in PBS. The secondary antibodies, goat anti-mouse conju-
gated with Texas red (stock 1.5 mg/ml) and goat anti-rabbit
conjugated fluorescein (stock 1.5 mg/ml) (both from Jack-
son Laboratories) were diluted 1:50 in IF buffer along with
a DNA counterstain, Hoechst (Sigma), diluted at 1:1000 (1
mg/ml stock in DMSO) to reveal nuclear morphology. This
solution was added to the cells for 1 h at room temperature.
The cells were then washed extensively in PBS and a
coverslip was mounted over the cells using FluorMount G
(Southern Biotechnology Associates Inc.). A Zeiss Axiomat
immunofluorescence microscope was used for visualization
and microphotography.
For localization of Golgi and endosome compartments,
keratinocytes were transfected 24 h postplating with 2 g
DNA of TGN-38-GFP or cellubrevin-GFP, respectively
(Miesenbock et al., 1998; Sankaranarayanan et al., 2000).
Three microliters of FuGene 6 (Roche) was used for each
transfection according to the manufacturer’s protocol. The
cells were processed for imaging 24 h after transfection
using the fixation methods described above.
Keratinocyte transduction
Primary HFKs were isolated from neonatal foreskins as
described previously (Schlegel 88) and cultured in keratin-
ocyte growth medium (KGM, Invitrogen). Keratinocytes
(passage 1 (P1)) were infected with retroviruses (LXSN,
wt16E5, and 16E5*) at a multiplicity of infection of 10:1
and selected continuously in G418 (100 g/ml). Resistant
cells were pooled and passaged at a ratio of 1:5.
Immunoprecipitation and immunoblotting of E5 proteins
For direct immunoprecipitation, 3  106 cells were
plated in 100-mm tissue culture plates (Falcon). Twenty-
four hours later the cells were washed with PBS and then 4
ml of labeling medium (DMEM without cysteine and me-
thionine (BioWhitaker)) was added to each plate. The cells
were starved for 4 h and then 15 l (100 Ci) S35 Label Mix
(NEN) was added for an additional 3 h. The cells were then
washed in cold PBS, lysed in 1 ml of Bolen-modified
radioimmunoprecipitation assay (RIPA) buffer (20 mM
Mops, 150 mM NaCl, 1 mM EDTA, 1% NonidetP-40, 1%
deoxycholate, 0.1% SDS), and further disrupted by passage
through a 22-gauge needle (Becton Dickson). Lysates were
then clarified by centrifugation.
For the immunoprecipitation/immunoblotting analysis, 3
 106 cells were plated in 100-mm tissue culture dishes.
Twenty-four hours later, the cells were washed with PBS
and then lysed in 1 ml of RIPA buffer. Cells were disrupted
by passage through a 22-gauge needle and the lysates were
clarified by centrifugation. Protein concentrations for both
the IP and IP/IB were determined using the Bio-Rad deter-
gent compatible kit as previously described (Suprynowicz et
al., 2000). For both the IP and IP/IB, equal amounts (350
g) of protein (in 1 ml) were immunoprecipitated using 4 l
of the AU1 antibody and 30 l of a 50% slurry of protein A
beads (Pierce). The IP conditions were as described previ-
ously (Suprynowicz et al., 2000). The Western blot was
carried out using the AU1 antibody at 1:1000 under condi-
tions previously described (Suprynowicz et al., 2000).
Quantitative RT-PCR of E5 mRNA
HFKs infected with LXSN, wt16E5, or 16E5* retrovi-
ruses were plated at equal cell numbers (3  106 per
100-mm plate). Twenty-four hours later RNA was isolated
using the RNAqueous kit (Ambion). The reverse transcrip-
tion reaction was carried out using the High Capacity cDNA
Archive Kit (Perkin Elmer Applied Biosystems) with
both oligo(dT) and random hexamer primers. The PCR
oligonucleotides for the neomycin gene were S-5-CAT-
CCTGCCATTCGACCAC-3 and AS-5-GACAAGACCG-
GCTTCCATCC-3. For the wt16E5 gene, the primer
oligonucleotides were S-5-GATACTGCATCCACAACA-
TTA-3 and AS-5-TAGACACAGACAAAAGCAGC-3.
The PCR oligonucleotides for the 16E5* gene were S-5-
ATACTGCATCCACAACACTG-3 and AS-5-TAGACA-
CAGACAGCAGCAGG-3. Real-time PCR was performed
using the SYBR Green Kit (Perkin Elmer Applied Biosys-
tems) on an iCycler real-time PCR machine (Bio-Rad).
Dimerization study
Four hundred thousand COS-1 cells were transfected
with empty vector (pJS55) or vectors encoding for wt16E5
and 16E5* using the CaPO4 method previously described
(Sparkowski et al., 1994). Forty-eight hours after transfec-
tion the cells were lysed in 1 ml of RIPA buffer and further
disrupted by passage through a 22-gauge needle. Lysates
were clarified by centrifugation. Equal amounts (500 g) of
protein (in 1 ml) were immunoprecipitated using 4 l of the
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AU1 antibody (Covance) and 30 l of a 50% slurry of
protein A beads (Pierce). The IP conditions are as men-
tioned above. For the samples that were treated with 10%
-mercaptoethanol 45 l of 2 sample buffer with 10%
-mercaptoethanol was added and then the samples were
boiled. For those samples under nonreducing conditions, the
protein was eluted off the beads in 2 sample buffer with-
out 10% -mercaptoethanol. All samples were boiled for 7
min at 100°C before being loaded on Tris–glycine gels
(Invitrogen). The Western blot to detect the E5 protein was
done using AU1 at 1:1000 under conditions previously
described (Suprynowicz et al., 2000).
Focus formation assay
Five hundred cells from each line were plated in 100-mm
tissue culture plates in a lawn of 1  106 NIH3T3 cells.
Cultures were grown for 2–3 weeks until foci were visible
and were then stained with 0.1% methylene blue (Sigma)
dissolved in methanol (Baker).
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